SEQUENCE LISTING

<110> Watson, John W.
     Andrews, Paul L.R.
     Woods, Anthony J.

<120> PROKINETIC AGENTS FOR TREATING GASTRIC HYPOMOTILITY AND RELATED
      DISORDERS

<130> 16613 (PC9731A)

<140> 09/476,253
<141> 1999-12-30

<160> 12

<170> PatentIn version 3.2

<210> 1
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> misc_feature
<222> (1)..(1)
<223> Phe is stereoisomer

<220>
<221> misc_feature
<222> (4)..(4)
<223> Trp is stereoisomer

<220>
<221> misc_feature
<222> (5)..(5)
<223> Xaa is Orn

<220>
<221> misc_feature
<222> (7)..(7)
<223> Xaa is Pen

<220>
<221> misc_feature
<222> (8)..(8)
<223> Thr is Thr-NH subscript 2

<400> 1

Phe Cys Tyr Trp Xaa Thr Xaa Thr
1   5

<210> 2

1

```
<211>   7
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   Synthetic peptide


<220>
<221>   misc_feature
<222>   (2)..(2)
<223>   Ala is stereoisomer

<220>
<221>   misc_feature
<222>   (7)..(7)
<223>   Gly is Gly-NH subscript 2

<400>   2

Tyr Ala Phe Asp Val Val Gly
1                   5


<210>   3
<211>   7
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   Synethetic peptide


<220>
<221>   misc_feature
<222>   (2)..(2)
<223>   Ala is stereoisomer

<220>
<221>   misc_feature
<222>   (7)..(7)
<223>   Gly is Gly-NH subscript 2

<400>   3

Tyr Ala Phe Glu Val Val Gly
1                   5


<210>   4
<211>   4
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   Synthetic peptide


<220>
```

```
<221>  misc_feature
<222>  (4)..(4)
<223>  Pro is Pro-NH subscript 2

<400>  4

Tyr Pro Phe Pro
1


<210>  5
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Phe is substituted with a methyl group

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Pro is Pro-NH subscript 2 and is stereoisomer

<400>  5

Tyr Pro Phe Pro
1


<210>  6
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  6

Arg Pro Pro Gly Phe Ser Pro Phe Arg
1                   5


<210>  7
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  7
```

Lys Arg Pro Pro Gly Phe Ser Pro Phe Arg
1   5   10

<210>   8
<211>   9
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   Synthetic peptide

<220>
<221>   misc_feature
<222>   (9)..(9)
<223>   Arg is des-Arg

<400>   8

Arg Pro Pro Gly Phe Ser Pro Phe Arg
1   5

<210>   9
<211>   10
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   Synthetic peptide

<220>
<221>   misc_feature
<222>   (10)..(10)
<223>   Arg is des-Arg

<400>   9

Lys Arg Pro Pro Gly Phe Ser Pro Phe Arg
1   5   10

<210>   10
<211>   9
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   Synthetic peptide

<220>
<221>   misc_feature
<222>   (9)..(9)
<223>   Arg is des- Arg

<400>   10

4

Arg Pro Pro Gly Phe Ser Pro Leu Arg
1   5

<210>   11
<211>   9
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   Synthetic peptide

<220>
<221>   misc_feature
<222>   (7)..(7)
<223>   Phe is stereoisomer

<400>   11

Arg Pro Pro Gly Phe Ser Phe Phe Arg
1   5

<210>   12
<211>   10
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   Synthetic peptide

<220>
<221>   misc_feature
<222>   (1)..(1)
<223>   Arg is stereoisomer

<220>
<221>   misc_feature
<222>   (4)..(4)
<223>   Xaa is trans-4-hydroxy-Pro

<220>
<221>   misc_feature
<222>   (6)..(6)
<223>   Xaa is Beta(2-thienyl)-Ala

<220>
<221>   misc_feature
<222>   (8)..(8)
<223>   Xaa is [D]-1,2,3,4-tetrahydroquinolin-3-yl-carbonyl

<220>
<221>   misc_feature
<222>   (9)..(9)
<223>   Xaa is (3as,7as)-octahydroindol-2-yl-carbonyl

5

<400> 12

Arg Arg Pro Xaa Gly Xaa Ser Xaa Xaa Arg
1   5   10